Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan

Executive Summary

• Japan’s Ministry of Health, Labor and Welfare granted Orphan Regenerative Medicine Product Designation to OTL‑200 (atidarsagene autotemcel) for early‑onset metachromatic leukodystrophy (MLD).
• The therapy also received Orphan Drug Designation and Priority Review from the Saudi Food and Drug Authority.
• Kyowa Kirin is preparing to initiate a clinical trial of OTL‑200 in Japanese children with MLD, advancing the path toward potential approval and commercial availability.

Key Details

• Designation Granted: Orphan Regenerative Medicine Product (Japan) for OTL‑200 targeting pre‑symptomatic late infantile, pre‑symptomatic early juvenile, and early‑symptomatic early juvenile MLD.
• Additional Designations: Orphan Drug Designation and Priority Review (Saudi Arabia).
• Therapeutic Profile: Ex vivo autologous hematopoietic stem cell gene therapy delivering functional ARSA gene via lentiviral vector; approved as Lenmeldy™ in the U.S. and Libmeldy® in Europe.
• Clinical Development: Kyowa Kirin preparing to initiate a Japanese clinical trial for OTL‑200 in children with early‑onset MLD.
• Strategic Impact: Provides a potential disease‑modifying treatment for an ultra‑rare, fatal neurodegenerative disorder with no approved therapies in Japan; supports Kyowa Kirin’s rare‑disease pipeline and global expansion of the product.

Notable Quotes

“We are very pleased that OTL‑200 has received designation as an Orphan Regenerative Medicine Product in Japan… This therapy is already being used in Europe and the United States, and it is highly regarded as a treatment that can restore enzymatic function with a single administration.” – Takeyoshi Yamashita, Ph.D., Executive Vice President & Chief Medical Officer, Kyowa Kirin

“Bringing these potentially transformative therapies to children and families in need is central to our mission… these designations represent important progress toward advancing OTL‑200 toward a potential regulatory approval in Japan and beyond.” – Bobby Gaspar, M.D., Ph.D., CEO, Orchard Therapeutics